Pacira BioSciences, Inc.
PCRXUS売上高
$726M
百万USD
営業利益
$19M
百万USD
純利益
$7M
百万USD
ROE
1.0%
最新FY
EPS
$0.16
USD / 株
配当
-
USD / 株
業績推移
収益性
キャッシュフロー
財務状況
四半期業績
| 年度 | 期 | 売上高 | 純利益 | EPS |
|---|---|---|---|---|
| FY2021 | Q1 | $119M | $10M | $0.23 |
| FY2021 | Q2 | $136M | $19M | $0.42 |
| FY2021 | Q3 | $128M | $18M | $0.39 |
| FY2021 | FY | $539M | $42M | $0.92 |
| FY2022 | Q1 | $158M | $7M | $0.15 |
| FY2022 | Q2 | $169M | $20M | $0.40 |
| FY2022 | Q3 | $167M | $-1M | $-0.02 |
| FY2022 | FY | $667M | $16M | $0.34 |
| FY2023 | Q1 | $160M | $-20M | $-0.43 |
| FY2023 | Q2 | $169M | $26M | $0.51 |
| FY2023 | Q3 | $164M | $11M | $0.23 |
| FY2023 | FY | $675M | $42M | $0.89 |
| FY2024 | Q1 | $167M | $9M | $0.19 |
| FY2024 | Q2 | $178M | $19M | $0.39 |
| FY2024 | Q3 | $169M | $-143M | $-3.11 |
| FY2024 | FY | - | $-100M | $-2.15 |
| FY2025 | Q1 | $169M | $5M | $0.10 |
| FY2025 | Q2 | $181M | $-5M | $-0.11 |
| FY2025 | Q3 | $180M | $5M | $0.12 |
| FY2025 | FY | $726M | $7M | $0.16 |
| FY2026 | Q1 | $177M | $3M | $0.07 |
財務データ
| 指標 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| 売上高 | - | - | $332M | $419M | $427M | $539M | $667M | $675M | - | $726M |
| 営業利益 | $-32M | $-25M | $16M | $10M | $46M | $90M | $60M | $88M | $-73M | $19M |
| 純利益 | $-38M | $-43M | $-0M | $-11M | $146M | $42M | $16M | $42M | $-100M | $7M |
| 総資産 | $391M | $628M | $689M | $831M | $1.3B | $2.1B | $1.7B | $1.6B | $1.6B | $1.3B |
| 純資産 | - | - | - | - | - | - | - | - | - | - |
| 自己資本 | $219M | $279M | $321M | $355M | $620M | $730M | $775M | $870M | $778M | $693M |
| 営業CF | - | - | - | $71M | $77M | $126M | $145M | $155M | $189M | $152M |
| EPS | $-1.02 | $-1.07 | - | - | $3.33 | $0.92 | $0.34 | $0.89 | $-2.15 | $0.16 |
| BPS | $5.84 | $6.86 | $7.79 | $8.44 | $14.13 | $16.29 | $16.87 | $18.71 | $16.82 | $17.12 |
| ROE | -17.3% | -15.2% | -0.1% | -3.1% | 23.5% | 5.7% | 2.1% | 4.8% | -12.8% | 1.0% |